Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1104 | 995 | 1156 | 1282 | 1326 | 1834 |
Fund Return | 10.4% | -0.54% | 15.65% | 8.64% | 5.81% | 6.25% |
Place in category | 330 | 244 | 202 | 142 | 118 | 65 |
% in Category | 54 | 39 | 33 | 28 | 28 | 17 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Royal London FTSE 350 Tracker Z Fun | 5.07B | 10.37 | 8.51 | 6.21 | ||
Royal London European Growth Fund C | 2.29B | -0.07 | 3.08 | 7.47 | ||
Royal London US Tracker Z Fund Accu | 1.4B | 27.00 | 11.94 | 15.08 | ||
Royal London UK Equity Income A | 1.16B | 9.38 | 8.63 | 6.11 | ||
Royal London UK Equity Income Fund | 1.16B | 9.82 | 9.11 | 6.73 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Index Unit Trust Accumulation | 14.46B | 11.13 | 7.80 | 6.10 | ||
All Share Index Unit Trust Income | 14.46B | 11.14 | 7.78 | 6.09 | ||
VG UK Plus GBP Accumulation | 14.46B | 11.14 | 7.80 | 6.12 | ||
VG UK Institutional Plus GBP Income | 14.46B | 11.15 | 7.79 | 6.11 | ||
UK Equity Tracker Fund D Acc | 11.69B | 10.48 | 8.11 | 6.25 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
AstraZeneca | GB0009895292 | 7.08 | 10,256.0 | +0.12% | |
Shell | GB00BP6MXD84 | 6.75 | 29.20 | -0.55% | |
HSBC | GB0005405286 | 5.67 | 760.80 | -0.56% | |
Unilever | GB00B10RZP78 | 4.95 | 55.04 | -0.61% | |
Relx | GB00B2B0DG97 | 2.84 | 3,629.00 | -0.68% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Strong Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review